Phase II Gemcitabine, Paclitaxel and Bevacizumab Combination as 1st Line Tx for Metastatic Breast CA
Trial ID or NCT#
NCT00403130
Status
NOT RECRUITING
Purpose
Single-institution phase 2 trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.
Official Title
Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer
Investigator(s)
George A Fisher
Medical oncologist,
Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine, Emeritus
Contact us to find out if this trial is right for you.
Contact
Mary Chen
6507238686
View on ClinicalTrials.gov
